Key Points
- Allison Swartz sold 4,657 shares of Progyny on March 3 at an average price of $17.40 for $81,031.80, trimming her stake by 4.93% to 89,879 shares; she also sold 2,199 shares on March 2 and 530 shares in December.
- Progyny beat quarterly expectations, reporting $0.48 EPS vs. $0.38 expected and $318.4M in revenue, and set FY2026 guidance of $1.83–$1.95 EPS (Q1 guidance $0.42–$0.45); analysts rate the stock a "Moderate Buy" with a $28.80 consensus price target.
Progyny, Inc. (NASDAQ:PGNY - Get Free Report) EVP Allison Swartz sold 2,199 shares of the company's stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $17.27, for a total transaction of $37,976.73. Following the completion of the sale, the executive vice president directly owned 97,378 shares in the company, valued at $1,681,718.06. This represents a 2.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Allison Swartz also recently made the following trade(s):
- On Tuesday, March 3rd, Allison Swartz sold 4,657 shares of Progyny stock. The shares were sold at an average price of $17.40, for a total transaction of $81,031.80.
- On Thursday, December 4th, Allison Swartz sold 530 shares of Progyny stock. The stock was sold at an average price of $24.59, for a total value of $13,032.70.
Progyny Trading Down 0.1%
NASDAQ:PGNY traded down $0.01 during trading hours on Thursday, reaching $17.78. 1,168,133 shares of the company traded hands, compared to its average volume of 1,579,020. The business's 50-day moving average price is $23.40 and its two-hundred day moving average price is $23.00. Progyny, Inc. has a 1 year low of $16.75 and a 1 year high of $28.75. The stock has a market capitalization of $1.46 billion, a P/E ratio of 27.35, a P/E/G ratio of 1.19 and a beta of 1.01.
Progyny (NASDAQ:PGNY - Get Free Report) last released its earnings results on Thursday, February 26th. The company reported $0.48 EPS for the quarter, topping analysts' consensus estimates of $0.38 by $0.10. The firm had revenue of $318.40 million for the quarter, compared to analysts' expectations of $314.26 million. Progyny had a return on equity of 11.37% and a net margin of 4.54%.The company's quarterly revenue was up 6.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.42 earnings per share. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. As a group, equities analysts anticipate that Progyny, Inc. will post 0.6 EPS for the current year.
Analyst Ratings Changes
Several research firms recently issued reports on PGNY. JPMorgan Chase & Co. set a $35.00 price objective on Progyny in a research report on Wednesday, January 21st. BTIG Research reaffirmed a "buy" rating on shares of Progyny in a report on Wednesday, January 21st. Canaccord Genuity Group increased their price objective on Progyny from $23.00 to $26.00 and gave the company a "hold" rating in a research report on Monday, November 17th. Citigroup raised Progyny to an "outperform" rating in a research report on Tuesday, January 20th. Finally, Barclays initiated coverage on shares of Progyny in a research note on Monday, December 8th. They set an "overweight" rating and a $29.00 target price on the stock. Eight research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $28.80.
View Our Latest Stock Analysis on PGNY
Institutional Investors Weigh In On Progyny
Several hedge funds and other institutional investors have recently modified their holdings of PGNY. Royal Bank of Canada lifted its position in Progyny by 384.8% during the first quarter. Royal Bank of Canada now owns 13,027 shares of the company's stock valued at $291,000 after purchasing an additional 10,340 shares in the last quarter. Amundi lifted its position in shares of Progyny by 103.8% during the 1st quarter. Amundi now owns 11,419 shares of the company's stock valued at $264,000 after buying an additional 5,817 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Progyny by 6.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,032 shares of the company's stock valued at $5,630,000 after acquiring an additional 14,297 shares during the period. Nisa Investment Advisors LLC lifted its holdings in Progyny by 249.3% during the second quarter. Nisa Investment Advisors LLC now owns 11,613 shares of the company's stock valued at $255,000 after purchasing an additional 8,288 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd boosted its position in shares of Progyny by 88.0% in the second quarter. Y Intercept Hong Kong Ltd now owns 56,196 shares of the company's stock worth $1,236,000 after purchasing an additional 26,310 shares during the period. 94.93% of the stock is currently owned by hedge funds and other institutional investors.
About Progyny
(
Get Free Report)
Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company's digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.
The core of Progyny's offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
